Bristol-Myers Squibb Company / ImClone Systems Incorporated
2001 · Licensing/Option · $2.0B · Complete
Announcement Sentiment
50
Neutral / mixed
BMS-ImClone Erbitux (cetuximab) co-development/commercialization; $1B equity tender at 75% premium for 19.9% stake plus $1B in milestones. Renegotiated 2002 after FDA RTF letter.